News
Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback